Pacira holder discloses 7.3% stake, pushes board changes
Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company. The group, led by Pedro Escudero, filed Amendment No. 3 to Schedule 13D.
Using 40,489,894 shares outstanding as of February 23, 2026, DOMA and related entities disclose various stakes, including 4.9% held by Doma Perpetual LO Equity Master Fund and 2% reported for The John Templeton Foundation. On March 11, 2026, Doma Master Fund notified Pacira it intends to nominate three directors at the 2026 annual meeting and to solicit proxies.
In a March 12, 2026 press release incorporated in the filing, DOMA called for chief executive officer Frank Lee to be replaced and urged the board to appoint an interim CEO. DOMA also stated its view that Pacira’s stock price has declined over several years while expenses and management compensation have increased, and urged the board to run a formal sale process to maximize value for shareholders.
Insights
DOMA discloses a 7.3% Pacira stake and launches a board and CEO challenge.
DOMA Perpetual Capital Management and affiliates report beneficial ownership of 2,936,794 Pacira shares, or 7.3% of outstanding common stock based on 40,489,894 shares as of February 23, 2026. This positions them as a meaningful shareholder with enough scale to mount an activist campaign.
The filing describes Doma Master Fund’s notice of intent to nominate three directors at the 2026 annual meeting and to solicit proxies. The group’s press release, incorporated by reference, states that it wants CEO Frank Lee replaced, an interim CEO appointed, and a formal sale process initiated to “maximize” asset value. These are the filers’ stated opinions and objectives.
If the slate gains support, Pacira’s governance, strategic direction, and leadership could shift, but outcomes depend on shareholder voting at the annual meeting and any board response. Future company disclosures around the nomination contest and any consideration of strategic alternatives will further clarify how this activist effort develops.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Pacira BioSciences (PCRX) does DOMA report in this Schedule 13D/A?
What board actions is DOMA seeking at Pacira BioSciences (PCRX)?
What leadership change at Pacira BioSciences (PCRX) does DOMA advocate?
What strategic changes does DOMA urge for Pacira BioSciences (PCRX)?
Which entities are included as reporting persons in this Pacira (PCRX) Schedule 13D/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.